The biologics revenue declined 16 percent driven by negative sales of Infuse in the United States, continuing a downward trend since last summer. The drop was offset partially by revenue growth in other biologics areas.
The international sales for the company’s spine business increased 8 percent. The core spine revenue dropped only 3 percent.
For the full year, Core Spinal revenue reached $2.4 billion, slightly lower than the $2.5 billion reported last year. Spinal biologics revenue also dropped to $800 million for the full-year report.
More Articles on Orthopedic Devices:
Benvenue Medical Appoints 2 New Board Members
Department of Justice Ends 4-Year Investigation of Infuse
AxioMed Receives CE Mark for Freedom Cervical Disc
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
